Gain Therapeutics (GANX)
(Real Time Quote from BATS)
$1.06 USD
0.00 (0.00%)
Updated Aug 2, 2024 03:00 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Brokerage Reports
Gain Therapeutics, Inc. [GANX]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Leadership Transition; Equity Financing Completed; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Abstract Accepted at European Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Key Legislation Passes Congress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Generates Positive Early Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Continues to Show Promise; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Preclinical Efficacy Profile Remains Intriguing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Progress Continues; Equity Financing; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Milestones Approaching; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Phase 1 Trial Dosing Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Phase 1 Healthy Volunteers Trial Near-Term Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Potential Highlighted in Poster Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Transition Into Clinical Development; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Parkinson''s Disease Prioritization; New Finance Chief Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Leadership Transition; 3Q22 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
New Animal Model Data Strengthen Parkinson?s Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Preclinical Datasets Presented; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Positive Preclinical Data Presented on Parkinson''s Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
New Preclinical Data Showcases Gaucher Program Strength; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R